Clinical Study Reveals Seaweed Extract Alleviates Prostate Symptoms Effectively
In a groundbreaking study conducted by Australian biotechnology firm Marinova, the efficacy of a unique seaweed extract in alleviating benign prostatic hyperplasia (BPH) symptoms was demonstrated. This randomized, double-blind, placebo-controlled clinical trial explored the effects of Fucoidan, a naturally occurring substance sourced from brown seaweed, specifically targeting men afflicted with BPH.
BPH is a prevalent health concern among men worldwide, with estimates indicating that 50-60% of men in their sixties and a staggering 90% in their eighties experience this condition. While typically non-life-threatening, BPH can lead to urinary symptoms such as difficulty urinating, weak urine flow, and increased urinary frequency, significantly impairing the quality of life.
Dr. Barbara Wimmer, the lead researcher, highlighted the gap in the clinical investigation of natural compounds that effectively support prostate health, stating, “Very few natural agents have been clinically validated for their role in prostate health. We were inspired to conduct this pioneering study owing to the documented bioactive properties of Fucoidan.”
The 90-day study engaged 88 men aged between 45 and 80 years who were suffering from moderate BPH. Participants were administered either a Fucoidan supplement or a placebo daily. The findings revealed compelling results, including:
The International Prostate Symptom Score (IPSS), a widely acknowledged measurement tool, was utilized to assess changes in BPH symptoms. Dr. Wimmer underscored the significance of these study results, affirming their clinical relevance and establishing Fucoidan's safety throughout the study duration. “We anticipate that these results will facilitate the market introduction of high-purity Fucoidan to mitigate benign prostate hyperplasia symptoms,” she added.
The results of this comprehensive study have been published in the esteemed journal, Research and Reports in Urology. Marinova focuses on research, development, and the manufacture of high-purity Fucoidans, which are utilized in dietary supplements, medical products, skincare formulations, and pharmaceuticals.
In pursuit of addressing a common yet challenging health issue, Marinova’s research signifies a substantial step toward alternative treatment pathways for BPH, showcasing the potential of natural compounds in enhancing men’s health. As further studies develop, Fucoidan may well emerge as a staple in prostate health management, drawing attention to the power of nature in modern medicine.
BPH is a prevalent health concern among men worldwide, with estimates indicating that 50-60% of men in their sixties and a staggering 90% in their eighties experience this condition. While typically non-life-threatening, BPH can lead to urinary symptoms such as difficulty urinating, weak urine flow, and increased urinary frequency, significantly impairing the quality of life.
Dr. Barbara Wimmer, the lead researcher, highlighted the gap in the clinical investigation of natural compounds that effectively support prostate health, stating, “Very few natural agents have been clinically validated for their role in prostate health. We were inspired to conduct this pioneering study owing to the documented bioactive properties of Fucoidan.”
The 90-day study engaged 88 men aged between 45 and 80 years who were suffering from moderate BPH. Participants were administered either a Fucoidan supplement or a placebo daily. The findings revealed compelling results, including:
- - Clinically significant improvements in overall BPH symptoms compared to the placebo.
- - A nine-fold enhancement in micturition symptoms, which encompass challenges such as incomplete emptying, interruptions, weak urine flow, and straining.
- - A two-fold improvement in storage symptoms, including frequency, urgency, and nocturia.
- - A noteworthy boost in quality of life stemming from urinary symptoms.
The International Prostate Symptom Score (IPSS), a widely acknowledged measurement tool, was utilized to assess changes in BPH symptoms. Dr. Wimmer underscored the significance of these study results, affirming their clinical relevance and establishing Fucoidan's safety throughout the study duration. “We anticipate that these results will facilitate the market introduction of high-purity Fucoidan to mitigate benign prostate hyperplasia symptoms,” she added.
The results of this comprehensive study have been published in the esteemed journal, Research and Reports in Urology. Marinova focuses on research, development, and the manufacture of high-purity Fucoidans, which are utilized in dietary supplements, medical products, skincare formulations, and pharmaceuticals.
In pursuit of addressing a common yet challenging health issue, Marinova’s research signifies a substantial step toward alternative treatment pathways for BPH, showcasing the potential of natural compounds in enhancing men’s health. As further studies develop, Fucoidan may well emerge as a staple in prostate health management, drawing attention to the power of nature in modern medicine.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.